Plozasiran for Severe Hypertriglyceridemia and Risk of Pancreatitis.
Two double-blind, placebo-controlled randomized trials evaluated plozasiran in 757 adults with severe hypertriglyceridemia.
Why it matters
Severe hypertriglyceridemia is associated with acute pancreatitis, and these trials found that plozasiran lowered triglyceride levels while the pooled analysis showed fewer pancreatitis events than with placebo.